Yulu Qianxing Biotech Joins Johnson & Johnson’s Global Incubator Network – JLABS Shanghai

Nov 06, 2025 19:55 CST Updated 19:55

Divamics

AI Drug Discovery Platform

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

Click on the "blue words" above to follow more exciting content.

[ October 2025, Shanghai, China ] Divamics Inc. (hereinafter referred to as "Divamics") announced that it has become a resident company of Johnson & Johnson’s Global Incubator Network – JLABS Shanghai. JLABS is a world-leading life science incubation platform. As an open innovation ecosystem, JLABS will empower and accelerate innovative research and development, speeding up solutions that improve human health and well-being, benefiting patients worldwide. With its leading position in the field of innovation, JLABS assists entrepreneurs in pharmaceuticals, medical devices, consumer health, and healthcare technology, bringing healthcare benefits to patients and consumers.

Yuancheng Ventures led the Series A financing of Divamics in May 2025.

Zheng Zheng, founder and CEO of Divamics, stated: "We are extremely honored to have successfully been selected through numerous rounds to join Johnson & Johnson JLABS Shanghai. We thank JLABS for recognizing Divamics. Joining JLABS will help us more efficiently advance the early drug discovery process from Hits→PCC within a compliant and secure experimental and translational environment. Relying on JLABS' global network will also enable Divamics to connect more effectively with partners worldwide, collaboratively exploring more practical pathways for cooperation and translation."

About Divamics

Divamics is an early-stage drug discovery company that leverages artificial intelligence, quantum mechanics, and molecular simulation algorithms as its core technologies. Since its inception, the company has been positioned to serve the global market, relying on its self-developed Divamics multi-scale molecular dynamics platform and Biotrajectory database. With its unique "Molecular Movie" drug design concept, Divamics provides AI-driven Hits-to-PCC integrated drug discovery services for biopharmaceutical companies. To date, it has served more than 50 pharmaceutical industry clients domestically and internationally, advancing over 80 new drug discovery pipelines through collaborations. The company’s headquarters is located in Suzhou, with a computing center in Beijing and a BD center in Singapore.

END

About Yuanbio Venture Capital

Yuansheng Venture CapitalIt is an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou BioBAY with a global reach. To date, it has invested in over 200 outstanding companies in the life sciences and healthcare field, spanning four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as cutting-edge medical technologies, achieving substantial investment returns. Among these, 20 companies have successfully gone public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. OrbiMed China has been repeatedly ranked among the Top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed China possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging professionalism, dedication, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.